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Abstract
Background: Endometriosis is a chronic, painful, and inflammatory disease characterized by extra-uterine growth
of endometrial tissues. Increased angiogenesis and resistance to apoptosis have been suggested to be involved in
pathogenesis and development of endometriosis. The objective of this study was to examine apoptosis potential
and angiogenesis contribution of eutopic (EuESCs) and ectopic (EESCs) endometrial stromal cells in patients with
endometriosis compared to endometrial stromal cells from non-endometriotic controls (CESCs).
Methods: Stromal cells were isolated by enzymatic digestion of ectopic (n = 11) and eutopic (n = 17) endometrial
tissues from laparoscopically-confirmed endometriotic patients. Endometrial stromal cells of 15 non-endometriotic
patients served as control. Following cell characterization by immunofluorescent staining and flow cytometry using
a panel of antibodies, the total RNA was isolated from the cultured cells, and analyzed for the expression of genes
involved in apoptosis (Bcl-2, Bcl-xL, Bax, and caspase-3) and angiogenesis [vascular endothelial growth factor-A
(VEGF-A) and hepatocyte growth factor (HGF)] by Real-time PCR.
Results: Significantly higher gene expression levels of Bcl-2 and Bcl-xL were found in EESCs compared with EuESCs
and CESCs (p < 0.01). The gene expression of Bax in EESCs, EuESCs, and CESCs was not statistically significant.
Furthermore, EuESCs exhibited a significantly lower caspase-3 gene expression compared with CESCs (p < 0.01) or
EESCs (p < 0.05). Regarding angiogenesis, VEGF-A gene expression in EESCs (p < 0.001) and EuESCs (p < 0.05) were
significantly higher compared with those of CESCs. EESCs exhibited a significantly higher HGF gene expression
compared with EuESCs (p < 0.05).
Conclusions: These findings suggest reduced propensity to apoptosis and increased angiogenesis potential of
EESCs, which may be involved in pathogenesis of endometriosis.
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Background
Endometriosis, defined as settlement of endometrial
glands and stroma in the extra-uterine cavity, is associ-
ated with irregular uterine bleeding, infertility, dyspar-
eunia, and chronic pelvic pain [1]. The highest
prevalence rates are typically found in couples with
fertility problems (5–50%), while it affects 10–20% of
reproductive-aged women [2]. Despite being quite com-
mon among women, our current understanding of the
etiology and pathophysiology of endometriosis is un-
known [3]. Several theories have been developed to
address the pathogenesis of endometriosis, but the retro-
grade menstruation proposed by Sampson in 1927 is the
most widely accepted one [4]. According to this theory,
uterine endometrial cells refluxed through fallopian
tubes into the peritoneal cavity during menstruation, im-
plant and initiate the endometriotic lesion formation.
Therefore, endometrial cells are likely to play an import-
ant role in the establishment of the disease [5].
Most recent reports have revealed an increased survival
capability of ectopic (EESCs) and eutopic endometrial
stromal cells (EuESCs) from patients with endometriosis
compared with cells from non-endometriotic women [6].
Higher capacity for survival and proliferation, and re-
sistance to apoptosis have been suggested to be in-
volved in implantation of these cells in patients with
endometriosis [6–8].
Apoptosis, maintains cellular homeostasis through
elimination of excess or dysfunctional cells from the
functional layer of the uterine endometrium during the
late secretory and menstrual phases of the menstrual
cycle [9]. Apoptotic activity of endometriotic cells is reg-
ulated by a diversity of regulatory factors. Among these
regulators, both anti-apoptotic (e.g. B-cell lymphoma/
leukemia-2 gene (Bcl-2) and B-cell lymphoma-extra
large (Bcl-xL)) and pro-apoptotic factors (e.g. Bax and
caspase-3) play a critical role in this process [9]. Several
studies pointed that endometrium from endometriotic
patients is less sensitive to apoptosis than that from
healthy controls [10, 11].
Besides of apoptosis resistance, endometriotic lesions
have been indicated to be highly vascularized with new
vessels that are essential for the successful implantation
of endometrial cells at ectopic sites [12]. The vascular
endothelial growth factor-A (VEGF-A) is a potent angio-
genic factor that induces endometrial cell proliferation
and is considered an important factor in uterine angio-
genesis [13]. Apart from VEGF-A, hepatocyte growth
factor (HGF), as a pleiotropic cytokine, has angiogenic,
mitogenic, and motogenic activities all of these may be
involved in the pathogenesis of endometriosis [14].
According to these arguments, here we assessed ex-
pression of some genes actively involved in regulation of
apoptosis (Bcl-2, Bcl-xL, Bax, and caspase-3) and
angiogenesis (VEGF-A and HGF) in EuESCs, EESCs and
endometrial stromal cells from non-endometriotic con-
trols (CESCs).
Materials and methods
Patients
The study group included twenty-five women with ovar-
ian endometriosis (mean age: 29 ± 7 years) and twenty
with benign gynecological conditions (mean age: 32 ± 6
years). Endometriosis in patient groups was confirmed
by laparoscopy and pathological examination. Partici-
pants in the control group did not exhibit any endome-
triotic lesions as carefully evidenced by a laparoscopic
surgeon. All of the subjects were at the proliferative
phase of the menstrual cycle with regular menstrual cy-
cles and none of them were on or had received any
hormonal or immunomodulatory treatment within 3
months before surgery. Patients with pelvic inflamma-
tory disease, adenomyosis, and any malignancy or
autoimmune disorders were excluded. All laparoscopic
procedures were done by the same experienced
gynecological surgeon. When endometriosis was diag-
nosed, the stage of the disease was determined according
to the revised American Society for Reproductive
Medicine classification system (ASRM 1996). Only
women with endometrioma who were at stage III-IV
were chosen for the study.
This study was approved by the Institutional Review
Board and the Ethics Committee for Medical Research
of the Avicenna Research Institute and all participants
signed written informed consent before participating in
the study.
Sample collection
The ectopic endometrial tissues were taken through
laparoscopy and eutopic samples were collected by
biopsy curette. All of the endometrial samples were
immediately transferred to the laboratory in tissue cul-
ture medium containing antibiotics, frozen in freezing
medium containing Dulbecco’s modified Eagle’s medium
(DMEM)-F12 (Sigma, USA), 10% fetal bovine serum
(FBS; Sigma, USA), and 20% dimethyl sulfoxide (Sigma,
USA) at − 80 °C and stored in liquid nitrogen until stro-
mal cell isolation. A fraction of each tissue was sent for
pathological confirmation of endometrioma.
From 25 endometriosis patients and 20 control pa-
tients, some samples were excluded from the study as a
result of tissue contamination, inconsistent pathology re-
port or absence of enough cell growth especially in case
of EESCs. Finally, cells from 17 eutopic and 11 ectopic
endometrial tissues of endometriotic patients and 15
eutopic endometrial tissue from non-endometriotic pa-
tients were used in this study.
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Isolation and culture of endometrial stromal cells (ESCs)
As previously described [15], ectopic and eutopic endo-
metrial tissues of patients with ovarian endometriosis
and eutopic endometrial tissues from control subjects
were thawed and digested at 37 °C for 1.5–2 h in the
presence of collagenase A and DNAse (Roche, USA).
The obtained single cells were cultured, and non-
adherent cells were removed by washing, and adherent
cells were allowed to grow and reach to approximately
80% confluence. The identity and purity of the ESCs
were evaluated by flow cytometry and immunofluores-
cent staining using a panel of antibodies against CD9,
CD10, CD29, CD34, CD38, CD44, CD45, CD73, CD105,
CD133 (all from Becton Dickinson Biosciences, USA),
FITC-vimentin, FITC-cytokeratin (both from Abcam,
USA), and PE-nestin (R&D Systems, USA) as described
elsewhere [15].
Quantitative real-time polymerase chain reaction
Total RNA of the ESCs was isolated according to the
protocol supplied with RNA-Bee Reagent (BioSite,
Sweden) according to the manufacturer’s instruction.
The purity and concentration of RNA samples were de-
termined using PicoDrop spectrophotometer (Picopetol,
UK). One microgram of total RNA was reverse tran-
scribed to complementary DNA (cDNA) according to
the protocol published elsewhere [16]. The beta-actin
gene was used as an internal control. Real-time PCR
analyses were carried out with the SYBR green dye-
based detection system (Takara, Japan) using the ABI
7500 thermocycler with fluorescence detection (Applied
Biosystems, USA). Reactions were denaturated at 95 °C
for 10 s, followed by 40 cycles of 95 °C for 5 s, 34 s of ex-
tension at 60 °C and finally a dissociation step consisting
of 95 °C for 15 s, 60 °C for 1 min, 95 °C for 15 s, and
60 °C for 15 s. At the end of the program, a melting
curve analysis was done and the PCR products were also
analyzed using gel electrophoresis to ensure the accuracy
of the amplifications. Reactions were done independently
in triplicate. The primer sequences and the size of
amplicons are shown in Table 1. The relative gene
expression of apoptosis and angiogenesis genes were
calculated by LinRegPCR.11.0 and REST software
(REST– version 2009).
Statistical analysis
In this study we used REST software (version 2009) to
test the group difference for significance using the Pair
Wise Fixed Reallocation Randomization Test. Expression
of each gene in each individual sample was first normal-
ized to the corresponding housekeeping gene and then
the ratio of normalized gene expression was compared
between two groups. Data were expressed as mean ±
standard error. A p < 0.05 was considered significant.
Results
ESCs exhibited a fibroblast-like appearance throughout
the culture period. The flow cytometric analysis showed
that isolated ESCs express mesenchymal origin antigens
such as CD9, CD29, CD44, CD73, and CD105 but were
negative for other origin markers, including CD34,
CD38, CD133, and CD45 (Fig. 1A). Immunofluorescence
staining of the propagated cells from all three sources
showed positive results for vimentin, a stromal cell cyto-
skeletal marker, and nestin but negative signal for cyto-
keratin, an epithelial marker (Fig. 1B), suggesting purity
of the isolated cells [15].
Expression of apoptosis and angiogenesis related gene
The gene expression levels of apoptosis and angiogenesis
were examined using real time PCR. Our results showed
significantly higher gene expression levels of Bcl-2
(Fig. 2a) and Bcl-xL (Fig. 2b) in EESCs compared to
EuESCs or CESCs (p < 0.01). Besides, EuESCs showed el-
evated levels of Bcl-xL, but not Bcl-2, gene expression
Table 1 Specifications of the primers used in this study
Target gene Accession No. Sequence 5′ to 3’ Amplicon size (bp)
Bcl-2-F BC027258,
NM_000633,
NM_000657
ATCGCCCTGTGG
ATGACTGAGT
127
Bcl-2-R GCCAGGAGAAA
TCAAACAGAGGC
Bcl-xL-F NM_001191,
NM_138578
GCCACTTACCTG
AATGACCACC
131
Bcl-xL-R AACCAGCGGTTG
AAGCGTTCCT
Bax-F NM_001291428,
NM_001291429,
NM_001291430,
NM_001291431
TCAGGATGCGT
CCACCAAGAAG
103
Bax-R TGTGTCCACGG
CGGCAATCATC
Caspase-3-F NM_004346,
NM_032991
GGAAGCGAATC
AATGGACTCTGG
146
Caspase-3-R GCATCGACATCT
GTACCAGACC
VEGF-A-F AF022375,
NM_001025366,
NM_001025367,
NM_001025368
TTGCCTTGCTGCT
CTACCTCCA
126
VEGF-A-R GATGGCAGTAGC
TGCGCTGATA
HGF-F NM_001010932.2,
NM_000601.5
GCAATTAAAACA
TGCGCTGACA
140
HGF-R TCCCAACGCTG
ACATGGAAT
β-Actin-F P60709 AGC CTC GCC T
TT GCC GA
174
β-Actin-R CTG GTG CCT G
GG GCG
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compared with CESCs (p < 0.05) (Fig. 2b and a respect-
ively). The difference of Bax gene expression between
EESCs, EuESCs, and CESCs was not statistically sig-
nificant (Fig. 2c). In addition, EuESCs showed a sig-
nificantly lower caspase-3 gene expression compared
with CESCs (p < 0.01) or EESCs (p < 0.05), but the dif-
ference between EESCs and CESCs was not significant
(Fig. 2d). VEGF-A gene expression by EESCs and
EuESCs were statistically higher compared with those
of CESCs (p < 0.001 and p < 0.05, respectively). Al-
though EESCs showed increased VEGF-A gene ex-
pression compared to EuESCs, but the difference was
not significant (Fig. 3a). HGF gene expression by
EESCs was statistically higher compared with EuESCs
(p < 0.05) (Fig. 3b).
Discussion
Endometriosis is a benign disease characterized by the
accumulation of cells in ectopic sites that could result
from either increased angiogenesis or the deficiency of
cells to undergo apoptosis [17].
Apoptosis is a form of programmed cell death that
removes old layers of functional endometrial cells at the
late menstruation secretory phase and in this way main-
tains cellular homeostasis in the menstrual cycle [18].
The results of our study showed significantly higher
gene expression levels of anti-apoptotic proteins, Bcl-2
and Bcl-xL, in EESCs compared with EuESCs or CESCs.
The pro-apoptotic caspase-3 gene revealed lower expres-
sion levels in EuESCs compared with CESCs or EESCs.
In addition, the difference of Bax gene expression be-
tween ESCs from all three sources was not statistically
significant. Extrinsic and intrinsic apoptotic pathways
may be involved in the pathogenesis of endometriosis
[19]. FasL/Fas interaction in extrinsic pathway leads to a
cascade of activation of initiator (caspase-8 and -9) and
effector
(caspase-3, − 6 and/or − 7) caspases, and finally apop-
tosis [19]. In a study by Nisio et al. caspase-8 but not
caspases 9 and 3 overexpressed in cortical tissue sur-
rounding endometriotic cysts and not cortex around
other benign cysts. These findings suggested that altered
Fig. 1 Immunophenotyping of ESCs of the study groups characterized by flow cytometric analysis and immunofluorescent staining. (A)
Representative flow cytometric analysis of CD9, CD10, CD29, CD34, CD38, CD44, CD45, CD73, CD105, and CD133 markers in ESCs. (B)
Representative immunofluorescent staining of ESCs exhibiting the expression of vimentin (a) and nestin (b) and negative immunoreactivity for
cytokeratin (c). ESCs from all three sources exhibited the same pattern
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cellular microenvironment could induce cellular damage
of normal tissue around endometriotic cyst [20]. Besides,
few studies have investigated Fas expression in endome-
triotic tissues. In a study by Harada et al., Fas showed
random expression in both eutopic and ectopic endo-
metrial tissues and authors suggested that Fas may be
less involved as an apoptosis regulator in both eutopic
and ectopic endometrial tissues [21]. On the other hand,
increased levels of inflammatory cytokines [22], growth
factors [23], and especially soluble/active FasL [24] have
been demonstrated in peritoneal fluid (PF) of women
with moderate to severe endometriosis compared to
women with early-stage disease or disease-free women.
Increased levels of soluble/active FasL in PF of endome-
triotic patients may contribute to increased apoptosis of
Fas-bearing immune cells [24]. Furthermore, in studies
by Garcia-Velasco et al. [25] and Selam et al. [26], in-
creased levels of platelet-derived growth factor (PDGF),
transforming growth factor-ß (TGF-ß), and IL-8 induced
expression of FasL by endometriotic stromal cells. The
authors speculated that elevated PF levels of these fac-
tors induces apoptosis of immune cells but not
endometriotic tissues via stimulation of FasL/Fas inter-
action. So based on the above findings it seems that
FasL/Fas mediated apoptosis pathway is not efficient in
elimination of endometriotic implants. Nevertheless, fur-
ther studies are needed to investigate FasL/Fas expres-
sion in endometrial and endometriotic tissues. So in this
study we aimed to investigate gene expression of factors
involved in intrinsic pathway of apoptosis.
Several gene expression studies related to apoptosis
were done on human endometrial cells during the differ-
ent phases of the menstrual cycle. These studies pro-
vided conflicting data regarding the difference in gene
expression levels involved in apoptosis between normal
endometrial tissue and endometrial tissue in women
with endometriosis [7, 27]. Although a large number of
studies have examined apoptosis through regulation of
Bcl-2 expression in endometriosis and a relatively few
studies have examined apoptosis through regulation of
Bax expression in endometriosis, very few studies have
monitored apoptosis through regulation of caspase-3
and Bcl-xL expression in endometriosis. With regard to
apoptosis, many studies showed an inverse correlation
Fig. 2 Bcl-2 (a), Bcl-xL (b), Bax (c), and caspase-3 (d) gene expression of isolated endometrial cells of studied groups. Each bar represents levels of
Bcl-2, Bcl-xL, Bax, and caspase-3 gene expression in two different endometrial stromal cell groups. 17 Eu, 11 E and 15 C were used in this study.
Data are expressed as mean ± standard error. E, stromal cells from the ectopic endometrium of patients with endometriosis (endometrioma); Eu,
stromal cells from the eutopic endometrium of patients with endometriosis; C, stromal cells from non-endometriotic controls,
*p < 0.05,** p < 0.01
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between the level of apoptosis and the stage of the dis-
ease [11, 28]. The Bcl-2 protein is probably the best pro-
tein for investigating apoptosis. Previous studies have
provided conflicting results regarding the difference in
Bcl-2 expression between normal endometrial tissue and
endometrial tissue in women with endometriosis. Ac-
cording to published studies, Bcl-2 was negative in most
of the ectopic endometrial tissues from endometrioma
[21, 29] and in another study, Bcl-2 expression was not
different between endometrial tissues of endometriotic
women and control counterparts [27, 30], but it was sig-
nificantly expressed to a greater extent in stromal cells
from ectopic tissues in another study [31]. On the other
hand, in a study by Meresman et al., an increased ex-
pression of Bcl-2 protein was found in eutopic endomet-
rium from women with endometriosis compared to the
control group only in late proliferative phase [17]. Simi-
larly to Jones et al. [31] study, in our study, Bcl-2 expres-
sion was increased significantly in EESCs.
Regarding Bcl-xL, gene expression of this anti-
apoptotic protein was not different between women with
endometriosis compared to healthy controls [32]. On
the contrary, we found increased mRNA expression of
Bcl-xL gene in EESCs compared with EuESCs and
CESCs. Apart from anti-apoptotic proteins, pro-
apoptotic proteins such as Bax and caspase-3 may have
fundamental roles in pathogenesis of endometriosis. Bax
gene is one of the well-characterized pro-apoptotic
genes, antagonizes the prosurvival activity of Bcl-2 [33].
Goumenou et al., found a strong inverse correlation be-
tween Bax and Bcl-2 expression in endometrioma [34].
In our study, we observed no statistically significant dif-
ferences between EESCs, EuESCs, and CESCs in terms
of Bax gene expression. Similarly, in previous studies,
the Bax gene expression did not differ between endo-
metrium from women with endometriosis and controls
[17, 27, 30, 32]. This finding may imply that not all
genes involved in regulation of apoptosis are modulated
in patients with endometriosis.
Caspase-3 is a member of the cysteine protease family,
plays a fundamental role in the activation of apoptosis
[35]. We studied caspase-3 gene expression in ESCs be-
cause of its important role in apoptosis but more so be-
cause in several of the studies related to endometriosis
that we studied it was altered or lost. In our study
caspase-3 gene expression was significantly lower in
EuESCs compared to CESCs. Similarly, in a study by
Wei et al., significantly lower expression of caspase-3
protein was found in ectopic and eutopic endometrium
of patients with endometriosis as compared with the
control group [36]. The discrepancy between results in
different studies could be explained by: 1) the properties
of separated cells (glandular versus stromal cells), 2) the
use of different endometriotic lesions (peritoneal versus
ovarian endometriosis), 3) various PCR techniques, 4)
difference in the preparation of cell and tissue culture
conditions, 5) difference in age and sexual phase of pa-
tients, and 6) difference in the stage of disease and in
the number of subjects.
In general, with regard to above findings, increased
gene expression of Bcl-2 and Bcl-xL as anti-apoptotic
proteins in EESCs and decreased gene expression of
Fig. 3 VEGF-A (a) and HGF (b) gene expression of isolated endometrial cells of studied groups. Each bar represents levels of VEGF-A and HGF
gene expression in two different endometrial stromal cell groups. 17 Eu, 11 E and 15 C were used in this study. Data are expressed as mean ±
standard error. E, stromal cells from the ectopic endometrium of patients with endometriosis (endometrioma); Eu, stromal cells from the eutopic
endometrium of patients with endometriosis; C, stromal cells from non-endometriotic controls. *p < 0.05, *** p < 0.001
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caspase-3 in EuESCs, may hamper apoptosis and lead to
abnormal cell growth in ectopic locations and the devel-
opment of endometriosis.
Regardless of the apoptosis, angiogenesis has an
essential role in the establishment and growth of endo-
metriotic lesions. The highly regulated angiogenesis is
responsible for maintaining normal reproduction and
endometrial growth and remodeling [12]. VEGF-A as
one of the most potent angiogenic factors, has a critical
role in physiological and pathological angiogenesis [37].
VEGF-A production is stimulated by growth factors,
hormones, cytokines, and hypoxia [38] and sources of
this factor in endometriosis include ectopic endomet-
rium and peritoneal macrophages [39]. Numerous stud-
ies have shown significantly increased VEGF levels in
the PF of endometriotic patients compared to controls
[40, 41]. Regarding VEGF-A gene expression, some stud-
ies showed unchanged [40, 42, 43], while other studies
showed increased VEGF-A gene expression in eutopic or
ectopic endometrium of women with endometriosis
compared to endometrium of non-endometriotic women
[44–48]. However, only one study investigated VEGF-A
expression in ESCs and in that study, VEGF-A expres-
sion was not different between EuESCs and CESCs [49].
Our results showed the increased VEGF-A gene expres-
sion in EESCs and EuESCs compared to CESCs. Dis-
crepancy in mentioned findings might be attributed to
difference in phases of the menstrual cycle as in a study
by Danastas et al. [44], VEGF-A gene expression was sig-
nificantly higher during menstruation than other phases.
Besides, type of endometriotic lesions affects VEGF-A
gene expression as higher VEGF-A gene expression was
observed in highly vascularized red peritoneal lesions
than black ones [12]. Genetic also plays a fundamental
role in this regard as some polymorphisms of the VEGF
gene might be protective or destructive for endometri-
osis [50].
Another important angiogenic factor is HGF. Lipo-
polysaccharides (LPS), inflammatory cytokines, and
prostaglandins stimulate HGF production in pelvic cav-
ity of endometriotic patients [51] and the peritoneum
and endometriotic stromal cells seem to be primary
sources of HGF in endometriosis [51, 52]. Increased
HGF expression has been shown in ectopic compared to
eutopic endometrial tissue in patient with endometriosis
[43] or non-endometriotic patients [53]. Regarding ESCs,
one study showed increased HGF protein expression in
EuESCs compared to CESCs [54] and in line with our
findings, in a study by Arablou et al. HGF gene expres-
sion was higher in EESCs compared to EuESCs [55].
HGF and its receptor c-met were shown to enhance
the degradation of extracellular matrix (ECM) and
stimulate invasion of shed eutopic and ectopic endomet-
rium via autocrine and paracrine pathways [56]. Besides,
HGF has been shown to promote VEGF-A-driven angio-
genesis [57]. So these findings imply that HGF may play
a role in the pathogenesis of endometriosis.
Conclusion
The present study demonstrated that not only less sus-
ceptibility of EESCs and EuESCs to apoptosis, but also
increased angiogenesis of these cells may result in their
continuing growth into ectopic locations and would be
fundamental to the pathophysiology of endometriosis
thus further investigations on apoptosis and angiogenesis
of EESCs and EuESCs compared to control groups are
needed to clarify the roles of these factors in the devel-
opment of endometriosis.
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